Self-administration of intravenous nicotine in male and female cigarette smokers

Neuropsychopharmacology

Volumn 33, Issue 4, 2008, Pages 715-720

  Sofuoglu, Mehmet ^a   Yoo, Sonah ^a   Hill, Kevin P ^a   Mooney, Marc ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Choice; IV nicotine; Nicotine; Nicotine abstinence; Self administration

Indexed keywords

NICOTINE; PLACEBO;

ARTICLE; BEHAVIOR; BLOOD PRESSURE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFECT; FEMALE; HEART RATE; HUMAN; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF MEDICATION;

ADULT; BLOOD PRESSURE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; INJECTIONS, INTRAVENTRICULAR; MALE; MIDDLE AGED; NICOTINE; NICOTINIC AGONISTS; SELF ADMINISTRATION; SEVERITY OF ILLNESS INDEX; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 39149101442     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301460     Document Type: Article

References (33)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders: DSM-IV, 4th edn. American Psychiatric Association: Washington, DC.
2. Benowitz NL (1999). Nicotine addiction. Prim Care 26: 611-631.
3. Benowitz NL, Jacob Pd (1990). Intravenous nicotine replacement suppresses nicotine intake from cigarette smoking. J Pharmacol Exp Therap 254: 1000-1005.
4. Chausmer AL, Smith BJ, Kelly RY, Griffiths RR (2003). Cocainelike subjective effects of nicotine are not blocked by the D1 selective antagonist ecopipam (SCH 39166). Behav Pharmacol 14: 111-120.
5. de Wit H, Bodker B, Ambre J (1992). Rate of increase of plasma drug level influences subjective response in humans. Psychopharmacology (Berlin) 107: 352-358.
6. de Wit H, McCracken SG (1990). Ethanol self-administration in males with and without an alcoholic first-degree relative. Alcohol Clin Exp Res 14: 63-70.
7. Djordjevic MV, Stellman SD, Zang E (2000). Doses of nicotine and lung carcinogens delivered to cigarette smokers. J Natl Cancer Inst 92: 106-111.
8. Foltin RW, Fischman MW (1992). Self-administration of cocaine by humans: choice between smoked and intravenous cocaine. J Pharmacol Exp Ther 261: 841-849.
9. Harvey DM, Yasar S, Heishman SJ, Panlilio LV, Henningfield JE, Goldberg SR (2004). Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology (Berlin) 175: 134-142.
10. Hatsukami DK, Thompson TN, Pentel PR, Flygare BK, Caroll ME (1994). Self-administration of smoked cocaine. Exp Clin Psychopharmacol 2: 115-125.
11. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO (1991). The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addictions 86: 1119-1127.
12. Henningfield JE, Goldberg SR (1983). Control of behavior by intravenous nicotine injections in human subjects. Pharmacol Biochem Behav 19: 1021-1026.
13. Henningfield JE, Miyasato K, Jasinski DR (1983). Cigarette smokers self-administer intravenous nicotine. Pharmacol Biochem Behav 19: 887-890.
14. Hughes JR, Hatsukami D (1986). Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43: 289-294.
15. Hughes JR, Hatsukami DK (1997). Effects of three doses of transdermal nicotine on post-cessation eating, hunger and weight. J Subst Abuse 9: 151-159.
16. Hughes JR, Rose GL, Callas PW (2000). Do former smokers respond to nicotine differently from never smokers? A pilot study. Nicotine Tob Res 2: 255-262.
17. Jones HE, Garrett BE, Griffiths RR (1999). Subjective and physiological effects of intravenous nicotine and cocaine in cigarette smoking cocaine abusers. J Pharmacol Exp Ther 288: 188-197.
18. Kenford SL, Smith SS, Wetter DW, Jorenby DE, Fiore MC, Baker TB (2002). Predicting relapse back to smoking: contrasting affective and physical models of dependence. J Consult Clin Psychol 70: 216-227.
19. Le Foll B, Goldberg SR (2006). Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology (Berlin) 184: 367-381.
20. McNair D, Lorr M, Dropperman L (1971). EITS Manual for the Profile of Mood States. Educational and Industrial Testing Services: San Diego, CA.
21. Nelson RA, Boyd SJ, Ziegelstein RC, Herning R, Cadet JL, Henningfield JE et al (2006). Effect of rate of administration on subjective and physiological effects of intravenous cocaine in humans. Drug Alcohol Depend 82: 19-24.
22. Perkins KA, Fonte C, Sanders M, Meeker J, Wilson A (2001). Threshold doses for nicotine discrimination in smokers and non-smokers. Psychopharmacology (Berlin) 155: 163-170.
23. Perkins KA, Grobe JE, Weiss D, Fonte C, Caggiula A (1996). Nicotine preference in smokers as a function of smoking abstinence. Pharmacol Biochem Behav 55: 257-263.
24. Rose JE, Behm FM, Westman EC (2001). Acute effects of nicotine and mecamylamine on tobacco withdrawal symptoms, cigarette reward and ad lib smoking. Pharmacol Biochem Behav 68: 187-197.
25. Rose JE, Corrigall WA (1997). Nicotine self-administration in animals and humans: similarities and differences. Psychopharmacology 130: 28-40.
26. Schneider NG, Olmstead RE, Nides M, Mody FV, Otte-Colquette P, Doan K et al (2004). Comparative testing of 5 nicotine systems: initial use and preferences. Am J Health Behav 28: 72-86.
27. Schneider NG, Terrace S, Koury MA, Patel S, Vaghaiwalla B, Pendergrass R et al (2005). Comparison of three nicotine treatments: initial reactions and preferences with guided use. Psychopharmacology (Berlin) 182: 545-550.
28. Soria R, Stapleton JM, Gilson SF, Sampson-Cone A, Henningfield JE, London ED (1996). Subjective and cardiovascular effects of intravenous nicotine in smokers and non-smokers. Psychopharmacology 128: 221-226.
29. Stoops WW, Lile JA, Fillmore MT, Glaser PE, Rush CR (2005). Reinforcing effects of methylphenidate: influence of dose and behavioral demands following drug administration. Psychopharmacology (Berlin) 177: 349-355.
30. Tancer M, Johanson CE (2003). Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend 72: 33-44.
31. Troisi II JR, Critchfield TS, Griffiths RR (1993). Buspirone and lorazepam abuse liability in humans: behavioral effects, subjective effects and choice. Behav Pharmacol 4: 217-230.
32. Watson D, Clark LA, Tellegen A (1988). Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 54: 1063-1070.
33. West R, Hajek P, Nilsson F, Foulds J, May S, Meadows A (2001). Individual differences in preferences for and responses to four nicotine replacement products. Psychopharmacology (Berlin) 153: 225-230.